New combo therapy shows promise in early breast cancer trial
NCT ID NCT05501769
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 25 times
Summary
This early-phase trial tested a new drug, ARV-471, combined with everolimus in 32 people with advanced ER+/HER2- breast cancer that had stopped responding to other treatments. The main goals were to check safety and find the best dose. This is not a cure, but aims to better control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clinical Trial Site
San Diego, California, 92037, United States
-
Clinical Trial Site
Santa Monica, California, 90404, United States
-
Clinical Trial Site
Washington D.C., District of Columbia, 20007, United States
-
Clinical Trial Site
Lake Mary, Florida, 32746, United States
-
Clinical Trial Site
Ann Arbor, Michigan, 48109, United States
-
Clinical Trial Site
Nashville, Tennessee, 37203, United States
-
Clinical Trial Site
Barcelona, 08028, Spain
-
Clinical Trial Site
Madrid, 28034, Spain
-
Clinical Trial Site
Valencia, 46018, Spain
Conditions
Explore the condition pages connected to this study.